Abstract
The hypothalamic decapeptide luteinizing hormone-releasing hormone (LHRH) is the prime controller of reproductive function (Fink, 1988). It performs this function, after being secreted from the hypothalamus into the hypophysial portal circulation, by binding and activating specific receptors on gonadotrophs (Stojilkovic et al, 1994).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albino A.P., Reed J.A. and McNutt N.S. (1997). Molecular biology of cutaneous malignant melanoma. In Cancer Principles and Practice of Oncology, 5th edn, eds. De Vita V.T., Hellman S., Rosenberg S.A. Philadelphia, Lippincott-Raven.
Breslow A. (1978). The surgical treatment of stage I cutaneous melanoma. Cancer Treat Rev, 5, 195–198.
Chatzaki E., Bax C.M.R., Eidne K.A., Anderson L., Grudzinskas J.G. and Gallagher C.J. (1996). The expression of gonadotropin releasing hormone and its receptor in endometrial cancer and its relevance as an autocrine growth factor. Cancer Res, 56, 2055–2065.
Conn P.M. and Crowley W.F. Jr. (1994). Gonadotropin-releasing hormone and its analogs. Ann Rev Med, 45, 391–405.
Danny W.A. and Wilson W.R. (2000). Tirapazamine: a bioreductive anticancer drug that exploit tumor hypoxia. Expert Opin Investig Drug, 9, 2889–2901.
Dondi D., Limonta P., Moretti R.M., Montagnani Marelli M., Garattini E. and Motta M. (1994). Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory loop. Cancer Res, 54, 4091–4095.
Dondi D., Moretti R.M., Montagnani Marelli M., Pratesi G., Polizzi D., Milani M., Motta M. and Limonta P.(1998). Growth inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer, 76, 506–511.
Emons G. and Schally A.V. (1994). The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecologi cal cancers. Hum Reprod, 9, 1364–1379.
Emons G., Ortmann O., Becker M., Irmer G., Springer B., Laun R., Holzel E, Schulz K.D. and Schally A.V. (1993). High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res, 54, 5439–5446.
Emons G., Weiss S., Ortmann O., Grundker C. and Schulz K.D. (2000). LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol, 142, 665–670.
Fink G. (1988). Gonadotropin secretion and its control. In The Physiology of Reproduction, eds. Knobil E. and Kneill J.D., pp. 1349-1377. NewYork, Raven Press.
Halaban R. (1996). Growth factors and melanoma. Semin Oncol, 23, 673–681.
Herlyn M., Clark W.H., Rodeck U., Mancianti M.L., Jambrosic J. and Koprowski H. (1987). Biology of tumor progression in human melanocytes. Lab Invest, 56, 461–474.
Hofmann U.B., Westphal J.R., van Muijen G.N.P. and Ruiter D.J. (2000). Matrix metalloproteinases in human melanoma. J Invest Dermatol, 115, 337–344.
Hwu W.J. (2000). New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology, 14, 25–28.
Imai A., Ohno T., Iida K., Fuseya T., Furui T. and Tamaya T. (1994). Gonadotropin-releasing hormone receptors in gynecological tumors. Cancer, 74, 2555–2561.
Kakar S.S., Musgrove L.C., Devor D.C., Sellers J.C. and Neill J.D. (1992).Cloning, sequencing and expression of human gonadotropin-releasing hormone (GnRH) receptor. Biochem Biophys Res Commun, 189, 289–295.
Kakar S.S., Grizzle W.E. and Neill J.D. (1994). The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol, 106, 145–149.
Kalra S.P. (1993). Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr Rev, 14, 507–538.
Karande A.A., Rajeshwari K., Schol D.J. and Hilgers J.H.M. (1995). Establishment of immunological probes to study human gonadotropin-releasing hormone receptors. Mol Cell Endocrinol, 114, 51–56.
Kottler M.L., Starzec A., Carre M.C., Lagarde J.P., Martin A. and Counis R. (1997). The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer, 71, 595–599.
Lazar-Molnar E., Hegyesi H., Toth S. and Falus A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine, 12, 547–554.
Limonta P., Dondi D., Moretti R.M., Maggi R. and Motta M. (1992). Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab, 75, 207–212.
Limonta P., Dondi D., Moretti R.M., Fermo D., Garattini E. and Motta M. (1993). Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab, 76, 797–800.
Lu C. and Kerbel R.S. (1994). Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Curr Opin Oncol, 6, 212–220.
Mackie R.M. (1998) Incidence, risk factors and prevention of melanoma. Eur J Cancer, 34 (Suppl 3), S3-S6.
Meyer T. and Hart I.R. (1998).Mechanisms of tumor metastasis. Eur J Cancer, 34, 214–221.
Natali P.G., Nicotra M.R., Bartolazzi A., Cavaliere R. and Bigotti A. (1993). Integrin expression in cutaneous malignant melanoma: associ ation of the α3/β1 heterodimer with tumor progression. Int J Cancer, 54, 68–72.
Oikawa M., Dargan C., Ny T. and Hsueh A.J.W. (1990). Expression of gonadotropinreleasing hormone and prothymosin-a messenger ribonucleic acid in the ovary. Endocrinology 127, 2350–2356.
Parkin D.M., Pisani P. and Ferlay J. (1999). Global cancer statistics. CA Cancer J Clin, 49, 33–64.
Schally A.V. (1994). Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs, 5, 115–130.
Shih I.M. and Herlyn M. (1993). Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol, 100, S196–S203.
Shih I.M. and Herlyn M. (1994). Autocrine and paracrine roles for growth factors in melanoma. In Vivo, 8, 113–123.
Stojilkovic S.S., Reinhart J. and Catt K.J. (1994).Gonadotropin-releasing hormone receptors. Structure and signal transduction pathways. Endocr Rev, 15, 462–499.
Stojilkovic S.S. and Catt K.J. (1995). Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Recent Prog Horm Res, 30, 161–205.
van Groeninghen JC, Kiesel L, Winkler D and Zwirner M (1998). Effects of luteinizing hormone-releasing hormone on nervous-system tumours. Lancet, 352, 372–373.
Wormald PJ, Eidne KA and Millar RP (1985). Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, cationic effects. J Clin Endocrinol and Metab, 61, 1190–1194.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Italia
About this paper
Cite this paper
Marelli, M.M., Moretti, R.M., Limonta, P. (2003). Investigation of LHRH Receptor Involvement in Melanoma Growth and Progression. In: Müller, E.E. (eds) Peptides and Non Peptides of Oncologic and Neuroendocrine Relevance. Springer, Milano. https://doi.org/10.1007/978-88-470-2085-6_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2085-6_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2170-9
Online ISBN: 978-88-470-2085-6
eBook Packages: Springer Book Archive